The nine-valent vaccine refers to the nine-valent HPV vaccine for the prevention of cervical cancer caused by human papillomavirus HPV infection. According to epidemiological studies, the nine-valent HPV vaccine prevents about 90% of cervical cancers, 70-85% of high cervical dysplasia (precancer), 85-95% of HPV-associated vulvar, vaginal and anal cancers, and 90% of acromegaly. Currently, there are three main types of HPV vaccines commonly available on the market: bivalent, quadrivalent and nine-valent, and the nine-valent HPV vaccine is the safest and most effective. The nine-valent vaccine can prevent nine HPV genotypes (6, 11, 16, 18, 31, 33, 45, 52 and 58) and is also ideal for Chinese people because it is the only one that can cover HPV 52 and 58, the common high-risk infection types for Chinese women. The nine-valent vaccine is recommended for women between the ages of 16 and 26, and is most effective when administered before the first sexual encounter, or if you have already had sex, the vaccine is equally effective. The nine-valent vaccine requires three doses, usually a second dose 2 months after the first dose and a third dose 4 months after the second. Vaccine recipients should be observed for 15-30 minutes after vaccination because a small number of female vaccine recipients may experience some adverse physiological reactions after receiving the cervical cancer vaccine, such as low fever, nausea, stomach pain, arm pain, redness and swelling at the vaccination site, etc. However, these discomfort symptoms are usually mild and will naturally subside with time. The cervical cancer vaccine has no effect on female fertility, but pregnant women, people with acute infection, and people with immunodeficiency should not be vaccinated; patients with cervical cancer undergoing treatment should wait until they finish treatment before being vaccinated. It is worth noting that although the nine-valent vaccine is 90% effective in preventing cervical cancer lesions, it does not eliminate them 100%. Therefore, you should go for regular cervical cancer screening regardless of whether you have received the vaccine or not. Prevention plus screening is a two-pronged approach to better protect women’s health from cervical cancer. References: [1] Liu Yuchi,Sun Limei,et al. Research progress of prophylactic nine-valent HPV vaccine[J]. Modern Oncology Medicine. 2017,25(5):827-829[2]Hu Guiqiong. Is cervical cancer vaccine important? Should we get it or not? [J]. Nutritional health guide.2019,43:63[3]Li Zhengxing,Sheng Yonghong. A survey of nine-valent human papillomavirus vaccination among female students in a higher education institution in Yunnan [J]. Journal of Practical Medical Technology. 2021,28(7): 847-850[4] Huang T, Li Dao K, et al. A meta-analysis of adverse reactions to nine-valent HPV vaccination versus quadrivalent HPV vaccination in young women[J]. World abstract of the latest medical information (serial electronic journal). 2018,18(72): 48-50